neutralAnecdotalMay 3, 2026
Approved-drug versus wellness use
Tesamorelin discussion often sits between its approved lipodystrophy context and broader body-composition interest.
Reddit / searchlow confidencereddit
Source Tesamorelin
Egrifta
Growth HormoneWeight LossApprovedApprovedPrescriptionSubQ
Popular for:Visceral fat reduction, growth hormone deficiency, lipodystrophy
24
Registered Trials
23
Trial Publications
87
PubMed References
Approved
Evidence Level
Overview
Tesamorelin (brand name Egrifta/Egrifta SV) is a synthetic 44-amino acid analogue of human growth hormone-releasing hormone (GHRH). The short version: people usually care about it for visceral fat reduction, growth hormone deficiency, lipodystrophy, but the strength of the evidence depends heavily on indication and study type.
Tesamorelin (brand name Egrifta/Egrifta SV) is a synthetic 44-amino acid analogue of human growth hormone-releasing hormone (GHRH). It is the only FDA-approved GHRH analogue, approved in November 2010 for reduction of excess abdominal fat (visceral adipose tissue) in HIV-infected patients with lipodystrophy. Developed by Theratechnologies Inc.
Research Snapshot
What the evidence says
ApprovedTesamorelin currently shows 24 registered trials from ClinicalTrials.gov, 23 PubMed trial publications (21 RCT-tagged), and 87 PubMed references matching the stored source query. Treat PubMed references as literature surface area, not a count of clinical trials.
Known vs uncertain
Known signals
- 24 registered trials are tracked from ClinicalTrials.gov intervention records.
- 23 PubMed clinical-trial publications are indexed.
- 21 PubMed randomized controlled trial publications are indexed.
- 87 PubMed references are tracked separately from trial counts and can include animal, in-vitro, review, mechanism, or clinical records.
Open questions
- Evidence strength may vary by indication, route, formulation, and population.
- Public anecdotes can highlight interest or concern but do not establish clinical efficacy.
- Regulatory status and compounding access can change independently from the research literature.
Mechanism of Action
Tesamorelin preserves the full 44-amino acid human GHRH sequence with an N-terminal trans-3-hexenoic acid modification on Tyr1.
Key Research Benefits
Visceral fat reduction: Phase III trials (LIPO-010, n=412; CTR-1011, n=404) demonstrated 15-20% reduction in visceral adipose tissue (VAT) at 26 weeks.
Liver fat reduction (NAFLD): Landmark Lancet HIV study showed significant reduction in liver fat and slowed fibrosis progression in HIV-associated NAFLD.
Pulsatile GH restoration: Restores natural GH pulsatility and increases IGF-1 and IGFBP-3 levels. GH-mediated benefits include improved body composition, recovery, and sleep quality.
Cognitive benefits: Ongoing research into cognitive outcomes. Some data suggests GH/IGF-1 restoration may support memory and executive function.
Preserves feedback loops: Unlike exogenous GH (somatropin), tesamorelin maintains hypothalamic-pituitary feedback, reducing the risk of GH axis suppression.
Clinical Evidence Summary
Research Pipeline
Preclinical
Animal
Phase I
Phase II
Phase III
Approved
24
Registered Trials
23
Trial Publications
21
RCT Publications
87
PubMed References
ClinicalTrials.govPubMed ESearchExact-name queryChecked May 3, 2026
Registered trials are ClinicalTrials.gov intervention records. Trial publications are PubMed records tagged as clinical trials or randomized controlled trials. PubMed references are broader source-query matches and can include animal studies, in-vitro work, reviews, mechanism papers, and trial publications.
24
Registered trials
23
Trial publications
21
RCT publications
87
PubMed references
28
Reviews
1
Meta-analyses
Registered trials source
Jun 1, 2026
Tesamorelin
Uses the exact compound name as a ClinicalTrials.gov intervention query.
View sourceTesamorelin has one of the strongest clinical evidence bases of any peptide therapeutic, with over 800 participants across Phase III trials.
- LIPO-010 (Phase III, n=412) — Demonstrated significant VAT reduction vs placebo at 26 weeks in HIV lipodystrophy patients. Led to FDA approval.
- CTR-1011 (Phase III, n=404) — Confirmatory trial showing 15-20% VAT reduction. Injection site reactions were the most common AE.
- Stanley et al. (Lancet HIV) — Landmark NAFLD study showing liver fat reduction and slowed fibrosis progression in HIV-associated populations.
- Ongoing research includes metabolic syndrome and cognitive outcome studies, though these remain investigational.
Key PubMed References
87 PubMed references · showing top 21 by relevance
View all on PubMedBody composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials.
Meta-Analysis
Badran AS, Helal A, Shata KS, et al. · Obesity research & clinical practice · 2026
PMID: 41545261Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.
Review
Rahman OF, Lee SJ, Seeds WA · Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2026
PMID: 41490200Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.
Review
Mayfield CK, Bolia IK, Feingold CL, et al. · The American journal of sports medicine · 2026
PMID: 41476424Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity.
Human Study
Ellis RJ, Vaida F, Hu K, et al. · The Journal of infectious diseases · 2025
PMID: 39813152Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors.
Human Study
Russo SC, Ockene MW, Arpante AK, et al. · AIDS (London, England) · 2024
PMID: 38905488Anecdotes & Sentiment
Public discussion, not clinical evidence
This section summarizes what people are talking about in public sources. It can be useful for spotting questions, hype cycles, and recurring concerns, but it is separate from the evidence sections above.
Side Effects & Safety
- **Common: **Injection site reactions (erythema, pruritus, pain, swelling) — up to 50.7% in trials.
Common: Injection site reactions (erythema, pruritus, pain, swelling) — up to 50.7% in trials. Peripheral edema (9.9%). Arthralgia/myalgia (3.7-7.7%). Paresthesias.
Metabolic: HbA1c elevation (≥6.5%) observed more frequently in tesamorelin groups vs placebo. FDA label recommends baseline and periodic glucose monitoring.
Antibody formation: Anti-tesamorelin IgG antibodies developed in ~50% of patients at 26-52 weeks. Cross-reactivity to endogenous GHRH in ~60% of antibody-positive patients. Efficacy appeared similar in antibody-positive and negative groups.
IGF-1 elevation: Expected pharmacologically. Persistent levels >3 SDS may warrant dose adjustment or discontinuation.
Contraindications: Active malignancy, pregnancy, known hypersensitivity (including mannitol), major hypothalamic-pituitary axis disruption, pituitary surgery/radiation/tumor.
Known Interactions
No curated interaction entry is live for Tesamorelin yet.
Until the interaction table is fully populated, use the interaction checker and related peptides below to explore adjacent compounds and likely research pairings.
Comparison Pages
Comparison pages
AllNo comparison page is linked yet.
Frequently Asked Questions
Research Disclaimer
This page is for research and educational purposes only. The information presented is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Regulatory status can vary by compound, formulation, indication, and jurisdiction. Check official labeling, registry records, and qualified professional guidance before making any health-related decision. The studies referenced are linked to their original PubMed sources for verification.